颈动脉支架应用CGuard MicroNET覆盖支架12个月的疗效:113例患者的单中心研究。

IF 2.2 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Angiology Pub Date : 2025-10-01 Epub Date: 2023-11-04 DOI:10.1177/00033197231213679
Konstantinos Tigkiropoulos, Katerina Sidiropoulou, Manolis Abatzis-Papadopoulos, Ioannis Lazaridis, Nikolaos Saratzis
{"title":"颈动脉支架应用CGuard MicroNET覆盖支架12个月的疗效:113例患者的单中心研究。","authors":"Konstantinos Tigkiropoulos, Katerina Sidiropoulou, Manolis Abatzis-Papadopoulos, Ioannis Lazaridis, Nikolaos Saratzis","doi":"10.1177/00033197231213679","DOIUrl":null,"url":null,"abstract":"<p><p>Dual layer mesh stents constitute a novel treatment option for patients who undergo carotid artery stenting (CAS). The aim of this prospective study is to report 12 month outcomes of patients who underwent CAS with CGuard (Inspire MD, Tel Aviv, Israel) microNET self-expanding stent with embolic protection system in a tertiary center from October 2018 to March 2022. Primary endpoints included in-stent restenosis >70% verified by ultrasound (DUS), ipsilateral transient ischemic attack (TIA), and stroke at 12 months. Secondary endpoints included cardiovascular-related mortality (stroke, myocardial infarction, heart failure) and all-cause mortality during follow-up. One hundred thirteen patients were included in the study (male 72.5%), symptomatic 47.8%. Median follow-up was 25 months (2-48). By 12 months, there was one in-stent occlusion that manifested as stroke (1/113, 0.8%) but no other forms of in-stent restenosis. Two patients experienced contralateral TIA (1.7%). CVRM was 3.5% (4 MI) and all-cause mortality was 6% at follow-up. This prospective study shows that CAS with CGuard MicroNET-covered stent is safe with minimal neurological adverse events at 12 months follow-up. Larger, and longer-term studies are necessary to define CGuard long-term safety and protection against carotid-related stroke.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"841-847"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"12-Month Outcomes of Carotid Artery Stenting With CGuard MicroNET-Covered Stent: A Single-Center Study in 113 Patients.\",\"authors\":\"Konstantinos Tigkiropoulos, Katerina Sidiropoulou, Manolis Abatzis-Papadopoulos, Ioannis Lazaridis, Nikolaos Saratzis\",\"doi\":\"10.1177/00033197231213679\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Dual layer mesh stents constitute a novel treatment option for patients who undergo carotid artery stenting (CAS). The aim of this prospective study is to report 12 month outcomes of patients who underwent CAS with CGuard (Inspire MD, Tel Aviv, Israel) microNET self-expanding stent with embolic protection system in a tertiary center from October 2018 to March 2022. Primary endpoints included in-stent restenosis >70% verified by ultrasound (DUS), ipsilateral transient ischemic attack (TIA), and stroke at 12 months. Secondary endpoints included cardiovascular-related mortality (stroke, myocardial infarction, heart failure) and all-cause mortality during follow-up. One hundred thirteen patients were included in the study (male 72.5%), symptomatic 47.8%. Median follow-up was 25 months (2-48). By 12 months, there was one in-stent occlusion that manifested as stroke (1/113, 0.8%) but no other forms of in-stent restenosis. Two patients experienced contralateral TIA (1.7%). CVRM was 3.5% (4 MI) and all-cause mortality was 6% at follow-up. This prospective study shows that CAS with CGuard MicroNET-covered stent is safe with minimal neurological adverse events at 12 months follow-up. Larger, and longer-term studies are necessary to define CGuard long-term safety and protection against carotid-related stroke.</p>\",\"PeriodicalId\":8264,\"journal\":{\"name\":\"Angiology\",\"volume\":\" \",\"pages\":\"841-847\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Angiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/00033197231213679\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197231213679","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

双层网状支架是颈动脉支架术(CAS)患者的一种新的治疗选择。本前瞻性研究的目的是报告2018年10月至2022年3月在一家三级中心使用CGuard(Inspire MD,以色列特拉维夫)带栓塞保护系统的微网自扩支架接受CAS治疗的患者12个月的结果。主要终点包括支架再狭窄>70%,经超声(DUS)、同侧短暂性脑缺血发作(TIA)和12个月时的卒中验证。次要终点包括随访期间心血管相关死亡率(中风、心肌梗死、心力衰竭)和全因死亡率。113名患者被纳入研究(男性72.5%),症状47.8%。中位随访时间为25个月(2-48)。到12个月时,有一例支架内闭塞表现为中风(1/113,0.8%),但没有其他形式的支架内再狭窄。随访时,2例患者出现对侧TIA(1.7%),CVRM为3.5%(4 MI),全因死亡率为6%。这项前瞻性研究表明,在12个月的随访中,使用CGuard MicroNET覆盖支架的CAS是安全的,神经系统不良事件最小。有必要进行更大规模、更长期的研究,以确定CGuard对颈动脉相关中风的长期安全性和保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
12-Month Outcomes of Carotid Artery Stenting With CGuard MicroNET-Covered Stent: A Single-Center Study in 113 Patients.

Dual layer mesh stents constitute a novel treatment option for patients who undergo carotid artery stenting (CAS). The aim of this prospective study is to report 12 month outcomes of patients who underwent CAS with CGuard (Inspire MD, Tel Aviv, Israel) microNET self-expanding stent with embolic protection system in a tertiary center from October 2018 to March 2022. Primary endpoints included in-stent restenosis >70% verified by ultrasound (DUS), ipsilateral transient ischemic attack (TIA), and stroke at 12 months. Secondary endpoints included cardiovascular-related mortality (stroke, myocardial infarction, heart failure) and all-cause mortality during follow-up. One hundred thirteen patients were included in the study (male 72.5%), symptomatic 47.8%. Median follow-up was 25 months (2-48). By 12 months, there was one in-stent occlusion that manifested as stroke (1/113, 0.8%) but no other forms of in-stent restenosis. Two patients experienced contralateral TIA (1.7%). CVRM was 3.5% (4 MI) and all-cause mortality was 6% at follow-up. This prospective study shows that CAS with CGuard MicroNET-covered stent is safe with minimal neurological adverse events at 12 months follow-up. Larger, and longer-term studies are necessary to define CGuard long-term safety and protection against carotid-related stroke.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Angiology
Angiology 医学-外周血管病
CiteScore
5.50
自引率
14.30%
发文量
180
审稿时长
6-12 weeks
期刊介绍: A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信